Literature DB >> 8907127

Mechanisms of action of calcium-sensitizing drugs.

H Haikala1, I B Linden.   

Abstract

This review compares the mechanisms of action of the calcium-sensitizing agents levosimendan, pimobendan, MCI-154, and EMD 53998. By using purified human recombinant troponin-C (cTnC), the role of cTnC as a target protein for these compounds was investigated. Accordingly, the calcium-dependent binding to cTnC in a cTnC-high-performance liquid affinity chromatography (HPLAC) column and the stabilizing effects of the compounds on the calcium-induced conformation of dansylated cTnC were studied. Only levosimendan showed calcium-dependent action on cTnC. Of the studied compounds, levosimendan was the most potent calcium sensitizer in skinned fiber experiments. Furthermore, EMD 53998 and MCI-154, but not levosimendan and pimobendan, increased myosin ATPase activity, indicating that they may enhance the cycling rate of myosin-actin crossbridges. By analyzing the velocity (dT/dt) of isometric tension development in paced papillary muscles, it was shown that levosimendan probably enhances the association rate but decreases the dissociation rate of myosin-actin crossbridges. These effects occurred before the peak twitch tension was achieved. Therefore, levosimendan does not seem to affect the actual relaxation phase. The other calcium sensitizers, however, appear to act mainly by decreasing the dissociation rate of crossbridges. The weak calcium-sensitizing effect of pimobendan may be based on indirectly mediated increase in affinity of cTnC for calcium. MCI-154 might act in a similar way but, like EMD 53998, MCI-154 also acts on myosin-actin crossbridges. We suggest that levosimendan binds in a calcium-dependent manner to the N-terminal domain of cTnC, which magnifies the extent of the contraction produced by cTnC when it is calcium-activated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8907127

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  29 in total

1.  Levosimendan: from coronary care to intensive care?

Authors:  Karen Stuart-Smith
Journal:  Intensive Care Med       Date:  2011-03-05       Impact factor: 17.440

2.  Integrative Methods for Studying Cardiac Energetics.

Authors:  Philippe Diolez; Véronique Deschodt-Arsac; Guillaume Calmettes; Gilles Gouspillou; Laurent Arsac; Pierre Jais; Michel Haissaguerre; Pierre Dos Santos
Journal:  Methods Mol Biol       Date:  2021

3.  Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.

Authors:  Ibrahim Halil Kurt; Kemal Yavuzer; Mustafa Kemal Batur
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

4.  Levosimendan restores the positive force-frequency relation in heart failure.

Authors:  Satoshi Masutani; Heng-Jie Cheng; Hideo Tachibana; William C Little; Che-Ping Cheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-13       Impact factor: 4.733

Review 5.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

6.  Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.

Authors:  P S Pagel; D A Hettrick; D C Warltier
Journal:  Basic Res Cardiol       Date:  1996 Jul-Aug       Impact factor: 17.165

7.  Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 8.  Levosimendan.

Authors:  D P Figgitt; P S Gillies; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  Levosimendan as treatment option in severe verapamil intoxication: a case report and review of the literature.

Authors:  Mirjam Osthoff; Christine Bernsmeier; Stephan C Marsch; Patrick R Hunziker
Journal:  Case Rep Med       Date:  2010-08-11

Review 10.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.